Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Xtandi Makes Strong Contribution to Astellas’s Half-Year Sales and Profits
Astellas Pharma reported strong growth in April-September in both sales and profits due mainly to growth in sales of products including the prostate cancer treatment Xtandi (enzalutamide) and its line of overactive bladder (OAB) treatments. An increase in gross profits…
To read the full story
Related Article
- Astellas Sees Sales Drop, but Profits Grow on Lower Costs
October 31, 2016
- Sakigake Designation System Very Useful: Astellas President
November 2, 2015
BUSINESS
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Voyxact PIII Data Confirm Kidney Function Stabilization in IgAN
August 5, 2026
- Perioperative Imfinzi Seen Advancing Gastric Cancer Care: Oncologist
August 5, 2026
- Teijin Still Seeking “Best Owner” for Legacy Drug Portfolio
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…